EP1349555A4 - Treatment of cancer by reduction of intracellular energy and pyrimidines - Google Patents

Treatment of cancer by reduction of intracellular energy and pyrimidines

Info

Publication number
EP1349555A4
EP1349555A4 EP01986104A EP01986104A EP1349555A4 EP 1349555 A4 EP1349555 A4 EP 1349555A4 EP 01986104 A EP01986104 A EP 01986104A EP 01986104 A EP01986104 A EP 01986104A EP 1349555 A4 EP1349555 A4 EP 1349555A4
Authority
EP
European Patent Office
Prior art keywords
pyrimidines
cancer
reduction
treatment
intracellular energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01986104A
Other languages
German (de)
French (fr)
Other versions
EP1349555A1 (en
Inventor
Daniel S Martin
Joseph R Bertino
Jason Koutcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of EP1349555A1 publication Critical patent/EP1349555A1/en
Publication of EP1349555A4 publication Critical patent/EP1349555A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
EP01986104A 2000-12-04 2001-12-04 Treatment of cancer by reduction of intracellular energy and pyrimidines Withdrawn EP1349555A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25099300P 2000-12-04 2000-12-04
US250993P 2000-12-04
PCT/US2001/046886 WO2002045720A1 (en) 2000-12-04 2001-12-04 Treatment of cancer by reduction of intracellular energy and pyrimidines

Publications (2)

Publication Number Publication Date
EP1349555A1 EP1349555A1 (en) 2003-10-08
EP1349555A4 true EP1349555A4 (en) 2007-04-25

Family

ID=22950034

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01986104A Withdrawn EP1349555A4 (en) 2000-12-04 2001-12-04 Treatment of cancer by reduction of intracellular energy and pyrimidines

Country Status (4)

Country Link
EP (1) EP1349555A4 (en)
AU (1) AU2002236569A1 (en)
CA (1) CA2436847A1 (en)
WO (1) WO2002045720A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381713B2 (en) 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
GB2530479A (en) * 2014-08-06 2016-03-30 Hilmar Meek Warenius Peptides useful for treating cancer
US11793877B2 (en) * 2015-10-06 2023-10-24 Rensselaer Polytechnic Institute Controlled drug release from electrospun fibers
GB201602409D0 (en) * 2016-02-10 2016-03-23 Warenius Hilmar M Compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023014A1 (en) * 1992-05-20 1993-11-25 Martin Daniel S Chemotherapeutic drug combinations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023014A1 (en) * 1992-05-20 1993-11-25 Martin Daniel S Chemotherapeutic drug combinations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COLOFIORE J R ET AL: "Biochemical modulation of tumor cell energy IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically induced tumor regression", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 50, no. 11, 27 November 1995 (1995-11-27), pages 1943 - 1948, XP002969684, ISSN: 0006-2952 *
KOUTCHER J A ET AL: "Radiation enhancement by biochemical modulation and 5-fluorouracil", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 39, no. 5, 1 December 1997 (1997-12-01), pages 1145 - 1152, XP002969686, ISSN: 0360-3016 *
MARTIN D S ET AL: "Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation", ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 7, 1996, pages 655 - 659, XP002969685, ISSN: 0959-4973 *
NORD L D ET AL: "Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 40, 1997, pages 376 - 384, XP002969688, ISSN: 0344-5704 *
See also references of WO0245720A1 *
STOLFI R L ET AL: "Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 52, no. 15, 1 August 1992 (1992-08-01), pages 4074 - 4081, XP002969683, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
EP1349555A1 (en) 2003-10-08
CA2436847A1 (en) 2002-06-13
AU2002236569A1 (en) 2002-06-18
WO2002045720A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2001288432A1 (en) Materials and methods to potentiate cancer treatment
EP1565187A4 (en) Methods of treating cancer and related methods
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
EP1320376A4 (en) Treatment of prostate cancer
HRP20030874A2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
HUP0300848A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
EG22612A (en) Pyrimidine compounds and their use
EP1463495A4 (en) Agents and methods for treatment of cancer
EP1373221A4 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
GB0126662D0 (en) Treatment of skin using laser radiation
AU5000001A (en) Treatment of vitiligo
PL357042A1 (en) Treatment of psoriasis
EP1349555A4 (en) Treatment of cancer by reduction of intracellular energy and pyrimidines
AU8113401A (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
GB0000035D0 (en) Treatment of skin conditions
IL149281A0 (en) Treatment of cancer
IL161923A0 (en) Reduction of electromagnetic radiation
AU2001297571A1 (en) Detection and treatment of prostate cancer
EP1646385A4 (en) Use of benzothiopenes to treat and prevent prostate cancer
IL164099A0 (en) Use of interleukin-19 to treat cervical cancer
GB0008161D0 (en) Treatment of cancer
AU8466601A (en) Methods of screening novel agents for use in cancer therapy and prevention
GB0115943D0 (en) Treatment and diagosis of cancer
GB0129451D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20070328

17Q First examination report despatched

Effective date: 20070906

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080118